VistaGen

VTGN NASDAQ
0.5912
-0.0185
-3.03%
Opening 11:53 08/21 EDT
Open
0.6112
Prev Close
0.6097
High
0.6500
Low
0.5900
Volume
141.82K
Avg Vol (3M)
257.79K
52 Week High
2.440
52 Week Low
0.3801
% Turnover
0.33%
Market Cap
25.20M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers VistaGen VTGN stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA). In addition to AV-101, the Company has developed a human pluripotent stem cell (hPSC) technology platform, which includes its in-vitro bioassay system, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs) long before testing in animal and human studies. The Company is focused on regenerative medicine (RM) applications using blood, cartilage, heart and/or liver cells derived from hPSCs.
MORE >

Recently

Name
Price
%Change